The equity ownership architecture of Pharmedic Pharmaceutical Medicinal Joint Stock Company (Ticker: PMC) has undergone a major transition, with Tasco Pharma Biologics and Pharmaceutical Company Limited formally establishing itself as a major institutional investor. Throughout May 2026, Tasco Pharma executed concentrated open-market and block accumulations to acquire an aggregate of 1,482,494 PMC shares, representing a 15.89% controlling interest in Pharmedic’s charter capital. The structural buyout, localized via negotiated transaction channels on the Hanoi Stock Exchange (HNX), is valued in excess of 200 billion VND.
The primary corporate transfer configurations and underlying operational parameters defining Pharmedic include the following variables:
-
High-Velocity Equity Attrition: On the opposing end of the transaction, Vietnam Pharmaceutical Investment and Business Joint Stock Company executed a near-total exit, trimming its equity exposure from 15.89% down to 4.29%. Financial observers highlighted that this divesting entity had only recently achieved major shareholder status in February 2026. This rapid divestment window spanning less than three months has triggered market speculation regarding whether the position was a short-term financial placement or a pre-arranged equity handoff.
-
Regulatory Sanctions and Quality Vulnerabilities: This cross-corporate handoff materialized precisely as the Drug Administration of Vietnam ordered a mandatory nationwide recall of Pharmedic’s baseline Sodium Chloride 0.9% ophthalmic solution. While the manufacturing infraction has not been characterized as a systemic threat to the firm’s core operations, the event compromises historical brand equity and raises questions regarding internal quality control oversight.
-
Q1 2026 Financial Performance: During the initial quarter of the fiscal year, Pharmedic generated net revenue of 139 billion VND, marking a 10% year-on-year expansion that supported a gross profit of roughly 61 billion VND. However, escalating administrative and operational overhead flatlined the company’s net profit after tax at approximately 23 billion VND. Crucially, revenue deductions inflated 147-fold to nearly 3 billion VND, driven almost exclusively by a surge in returned merchandise values, which reached 2.9 billion VND against a baseline of just 20 million VND in the prior year’s corresponding quarter.
-
Asset Metrics and Capital Structuring: By the conclusion of Q1, Pharmedic’s consolidated asset base settled at 395 billion VND (up 14% year-to-date), anchored by an expanding inventory value of 124 billion VND. Within the liability and equity ledger, while net equity sat at 255 billion VND, overall corporate liabilities climbed sharply to approach 140 billion VND, driven by accumulating short-term working capital demands.
Within public equity markets, negative headlines regarding the localized eye drop recall triggered a notable valuation correction for the PMC ticker. The pharmaceutical stock has retreated significantly from its historical trading high near 189,000 VND per share, establishing a localized consolidation floor around the 130,000 VND per share threshold.
Source: https://vnbusiness.vn/pharmedic-thay-mau-co-dong-lon-giua-lum-xum-thu-hoi-san-pham.html